NEXIUM

LOE Approaching

esomeprazole magnesium

NDAORALFOR SUSPENSION, DELAYED RELEASE
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active…

Clinical Trials (5)

NCT05267613Phase 3Recruiting

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

Started Jul 2022
50 enrolled
Erosive Esophagitis
NCT03562026N/ACompleted

S-CEI of Nexium in Paediatric Patients

Started Jun 2018
240 enrolled
Peptic Ulcer, Gastroesophageal Reflux
NCT02477475N/ACompleted

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Started Jul 2015
1,595 enrolled
Reflux Esophagitis
NCT01729182N/ACompleted

Nexium Capsules LDA Specific Clinical Experience Investigation

Started Jan 2013
2,363 enrolled
Gastric UlcerDuodenal Ulcer
NCT01562600N/ACompleted

Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

Started Apr 2012
1,634 enrolled
Gastric UlcerDuodenal Ulcer